Opus Genetics/$IRD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Opus Genetics
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
Ticker
$IRD
Sector
Primary listing
Employees
28
Headquarters
Website
Opus Genetics Metrics
BasicAdvanced
$331m
-
-$1.42
0.55
-
Price and volume
Market cap
$331m
Beta
0.55
52-week high
$5.81
52-week low
$0.90
Average daily volume
911k
Financial strength
Current ratio
7.131
Quick ratio
6.71
Long term debt to equity
-5.678
Total debt to equity
-5.678
Interest coverage (TTM)
-28.04%
Profitability
EBITDA (TTM)
-42.981
Gross margin (TTM)
-179.03%
Net profit margin (TTM)
-892.36%
Operating margin (TTM)
-359.13%
Revenue per employee (TTM)
$430,000
Management effectiveness
Return on assets (TTM)
-46.79%
Return on equity (TTM)
-7,594.60%
Valuation
Price to revenue (TTM)
25.635
Price to book
-6.34
Price to tangible book (TTM)
-6.34
Price to free cash flow (TTM)
-7.879
Free cash flow yield (TTM)
-12.69%
Free cash flow per share (TTM)
-0.517
Growth
Revenue change (TTM)
-12.22%
Earnings per share change (TTM)
-29.77%
3-year revenue growth (CAGR)
-33.96%
3-year earnings per share growth (CAGR)
16.90%
What the Analysts think about Opus Genetics
Analyst ratings (Buy, Hold, Sell) for Opus Genetics stock.
Opus Genetics Financial Performance
Revenues and expenses
Opus Genetics Earnings Performance
Company profitability
Opus Genetics News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs